Crossref
4152 PREOPERATIVE GLP-1 RECEPTOR AGONIST (GLP-1 RA) USE PREDICTS POSTOPERATIVE GLP-1 RA USE, BUT NOT GREATER PERCENT TOTAL WEIGHT LOSS (%TWL), 1-YEAR AFTER METABOLIC/BARIATRIC SURGERY (BMS)
Surgery for Obesity and Related Diseases · 2026-04 · 22 (4) · S64
DOI: 10.1016/j.soard.2026.02.213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgery for Obesity and Related Diseases, 2026-04.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). 4152 PREOPERATIVE GLP-1 RECEPTOR AGONIST (GLP-1 RA) USE PREDICTS POSTOPERATIVE GLP-1 RA USE, BUT NOT GREATER PERCENT TOTAL WEIGHT LOSS (%TWL), 1-YEAR AFTER METABOLIC/BARIATRIC SURGERY (BMS). Surgery for Obesity and Related Diseases, 22(4), S64. https://doi.org/10.1016/j.soard.2026.02.213
Vancouver
4152 PREOPERATIVE GLP-1 RECEPTOR AGONIST (GLP-1 RA) USE PREDICTS POSTOPERATIVE GLP-1 RA USE, BUT NOT GREATER PERCENT TOTAL WEIGHT LOSS (%TWL), 1-YEAR AFTER METABOLIC/BARIATRIC SURGERY (BMS). Surgery for Obesity and Related Diseases. 2026;22(4):S64. doi:10.1016/j.soard.2026.02.213
BibTeX
@article{euvimed2026,
title = {4152 PREOPERATIVE GLP-1 RECEPTOR AGONIST (GLP-1 RA) USE PREDICTS POSTOPERATIVE GLP-1 RA USE, BUT NOT GREATER PERCENT TOTAL WEIGHT LOSS (%TWL), 1-YEAR AFTER METABOLIC/BARIATRIC SURGERY (BMS)},
journal = {Surgery for Obesity and Related Diseases},
year = {2026},
volume = {22},
number = {4},
pages = {S64},
doi = {10.1016/j.soard.2026.02.213}
}
EUVIMED